Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 13/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.52 |
| ▸ | MAPK6 | Q16659 | 3/20 | 0.52 |
| ▸ | MAPKAPK3 | Q16644 | 2/20 | 0.47 |
| ▸ | MAP2K7 | O14733 | 3/20 | 0.45 |
| ▸ | DHODH | Q02127 | 2/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2857674 | 0.88 | MAP2K4 (0.60) | MAP2K4MAPK1MAPK6MAPKAPK3MAP2K7 | |
| SCHEMBL2861899 | 0.87 | MAP2K4 (0.58) | MAP2K4MAPK1MAPK6MAPKAPK3MAP2K7 | |
| SCHEMBL13635356 | 0.86 | TTK (0.50) | MAP2K4MAPK1MAPK6MAP2K7GSK3A | |
| SCHEMBL2864251 | 0.85 | MAP2K4 (0.54) | MAP2K4MAPK1MAPK6MAPKAPK3DHODH | |
| SCHEMBL2860783 | 0.83 | MAP2K4 (0.52) | MAP2K4MAPK1MAPK6MAPKAPK3MAP2K7 | |
| SCHEMBL2858476 | 0.82 | MAP2K4 (0.68) | MAP2K4MAPK1MAPK6MAPKAPK3CSNK2A2 | |
| SCHEMBL2859867 | 0.82 | MAP2K4 (0.81) | MAP2K4MAPK1MAPK6MAPKAPK3MAP2K7 | |
| SCHEMBL4338871 | 0.80 | MAP2K4 (0.43) | MAP2K4MAPK1MAP2K7GSK3AGSK3B | |
| Ethylene SCHEMBL27536148 | 0.80 | MAP2K4 (0.65) | MAP2K4MAPK1MAPK6MAPKAPK3CSNK2A2 | |
| SCHEMBL2870208 | 0.79 | GSK3B (0.51) | MAP2K4MAPK1MAP2K7GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| EP-1380576-B1 | 1H-INDAZOLE COMPOUNDS INHIBITING JNK | EISAI R&D MAN CO LTD (JP) | 2009-11-25 | — | — | EP | disclosed |
| EP-1380576-B1 | 1H-INDAZOLE COMPOUNDS INHIBITING JNK | EISAI R&D MAN CO LTD (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-6982274-B2 | 1H-indazole compound | EISAI CO., LTD. (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
| US-20040127538-A1 | Novel 1h-indazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1380576-A1 | NOVEL 1H-INDAZOLE COMPOUND | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203691-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | MAP2K4 61/4885MAPK1 1/4885MAPK6 24/4885 |
| US-20040127538-A1 | Novel 1h-indazole compound | MAPK1, MAPK14, MAPK3 | MAP2K4 53/4885MAPK1 1/4885MAPK6 5/4885 |
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | MAP2K4 61/4885MAPK1 1/4885MAPK6 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.